Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

Unraveling the Complexities of the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies

Jawaria Pervaiz[1], Khuzin Dinislam[2*], Yatsenko Victoria[3], Sakhautdinova Ilmira[4], Polinskaya Anastasia[5], Suleymanova Minura[3], Natalia Perehozheva[6], David Romanov[7], Khalikova Aigul[4], Baghdasaryan Amalia[8],

[1]Frontier Medical College, Abbottabad, Pakistan.

[2]Department of Nutrition and Food Hygiene, Harbin Medical University No. 157 Baojian Road, Nangang District, Harbin City, Heilongjiang Province, PR China, 15008.

[3]Voronezh State Medical University, N.N. Burdenko Russia.

[4]Bashkir State Medical University, Russia.

[5]First Moscow State Medical University, Russia.

[6]Privolzhsky Research Medical University, Russia.

[7]Kuban State Medical University, Russia.

[8]Pacific State Medical University, Russia

***Correspondence:** Khuzin Dinislam

Department of Nutrition and Food Hygiene, Harbin Medical University No. 157 Baojian Road, Nangang District, Harbin City, Heilongjiang Province, PR China, 15008.

(Received: 27 October 2023 Revised: 22 November Accepted: 26 December)

KEYWORDS
Tumor microenvironment (TME), Cancer progression, Immune cells, Stromal cells, Extracellular matrix (ECM), Treatment response

Abstract:

The tumor microenvironment (TME) plays a pivotal role in cancer progression and treatment response by orchestrating complex interactions among immune cells, stromal cells, and the extracellular matrix (ECM). In this review, we provide a comprehensive overview of recent advancements in understanding the dynamic interplay within the TME and its implications for cancer biology and therapy. We delve into the immune infiltrate within the TME, highlighting the significance of tumor-infiltrating lymphocytes (TILs) and immune checkpoints in modulating anti-tumor immunity. Additionally, we discuss immunosuppressive mechanisms mediated by regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and the development of novel immunotherapeutic strategies targeting these pathways. We explore the intricate crosstalk between cancer cells and stromal cells, focusing on cancer-associated fibroblasts (CAFs), endothelial cells, and pericytes. We examine how CAFs contribute to ECM remodeling and tumor progression, while endothelial cells and pericytes regulate tumor angiogenesis and vascular permeability. Furthermore, we elucidate the immunomodulatory roles of mesenchymal stem cells (MSCs) in shaping the TME and influencing treatment outcomes. We discuss the dynamic remodeling of the ECM and its impact on cancer cell behavior, metastasis, and therapeutic resistance. We highlight recent studies investigating ECM stiffness, composition, and mechanical properties, and their implications for cancer biology and therapy. In conclusion, understanding the complexities of the TME is essential for developing targeted therapeutic approaches that exploit vulnerabilities within the tumor microenvironment. By elucidating the role of immune cells, stromal cells, and ECM in cancer progression and treatment response, we aim to pave the way for more effective precision medicine strategies tailored to individual patients.

1. Background

Cancer is a complex and multifaceted group of diseases characterized by the uncontrolled growth and spread of abnormal cells (S. Ahmad et al., 2023; Mussa et al., 2022). It is one of the leading causes of morbidity and mortality worldwide, posing significant challenges to public health systems and societies (Hanahan, 2022). Cancer can develop in almost any tissue or organ in the body, and it arises from a combination of genetic, environmental, and lifestyle factors (Kaszak et al., 2020).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

The hallmark of cancer is the aberrant proliferation of cells, which can form tumors and invade surrounding tissues. These abnormal cells can also metastasize, spreading to distant sites in the body through the bloodstream or lymphatic system, leading to secondary tumors (Preethi, Lakshmanan, & Sekar, 2021). The process of cancer development, progression, and metastasis involves a complex interplay of genetic mutations, epigenetic alterations, and interactions with the tumor microenvironment (Al-Mhanna et al., 2022; Mohd Salim et al., 2023).

2. Characterization of Tumor-Infiltrating Lymphocytes (TILs)

Tumor-infiltrating lymphocytes (TILs) constitute a heterogeneous immune cell population present within tumors, pivotal in mounting immune responses against cancer (Fassler et al., 2022). Characterizing TILs is imperative for discerning their potential as prognostic indicators and therapeutic targets. TILs are identified by specific cell surface marker expression via techniques such as flow cytometry or immunohistochemistry (A. Ahmad et al., 2022). This enables the categorization of lymphocyte types (e.g., CD8+ cytotoxic T cells, CD4+ helper T cells, regulatory T cells) and the determination of their activation status. Additionally, T-cell receptor (TCR) analysis unveils TIL diversity and specificity, elucidating their capability to recognize and combat tumor cells (Wu, Mei, Liu, & Jiang, 2020). (Gomez-Macias et al., 2020) conducted a comprehensive analysis across multiple cancer types, demonstrating the prognostic significance of TILs and their correlation with improved patient outcomes.

Assessment of TIL cytotoxicity involves measuring their ability to directly eliminate tumor cells, either spontaneously or upon activation. Furthermore, analysis of cytokine production by TILs offers insights into their immunomodulatory roles within the tumor microenvironment (Paijens, Vledder, de Bruyn, & Nijman, 2021). Evaluating TIL proliferative potential through ex vivo culture is pivotal for adoptive cell therapy strategies. Utilizing image analysis techniques, the density and distribution of TILs across distinct tumor regions are evaluated, shedding light on their infiltration patterns and potential correlations with clinical outcomes (Zhang & Zhang, 2020). Examination of physical interactions between TILs and tumor cells elucidates immune evasion mechanisms and informs therapeutic interventions (Plesca et al., 2020). (Maibach, Sadozai, Seyed Jafari, Hunger, & Schenk, 2020) utilized single-cell RNA sequencing to dissect the heterogeneity of TIL subsets and elucidate their functional states within the tumor microenvironment.

Genetic analysis unveils the mutational landscape of TILs, unraveling their clonal diversity, tumor-specific adaptations, and resistance mechanisms (Federico et al., 2022). Characterization of TILs offers promising avenues for prognosis prediction and personalized therapeutic interventions. The abundance and composition of TILs within tumors serve as prognostic indicators, guiding treatment decisions (Sanchez et al., 2021). Adoptive cell therapy, leveraging isolated and expanded TILs, presents a personalized approach to cancer treatment. Furthermore, insights into TIL biology inform the development of novel drugs aimed at enhancing anti-tumor activity or overcoming immunosuppressive mechanisms in the tumor microenvironment (Ahmed et al., 2022; Ahmed et al., 2023). Remarkably, (Li et al., 2022) identified a subset of TILs expressing programmed death ligand 1 (PD-L1) in breast cancer, suggesting a potential mechanism of immune evasion in the tumor immune microenvironment.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727



Figure 1: Understanding the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies:

Immune Cell Infiltration (TILs influence tumor behavior (Boisson et al., 2021). Targeting them shows promise in treatment), Stromal Composition (Fibroblasts and ECM contribute to tumor growth. Targeting stromal elements disrupts tumor-supportive niches) (Baid et al., 2022). Angiogenesis (New blood vessels sustain tumor growth. Anti-angiogenic therapies limit progression) (Mastracci et al., 2020). Hypoxia and Nutrient Deprivation (Promote tumor aggressiveness. Alleviating hypoxia or enhancing nutrient delivery may improve outcomes) (Quan et al., 2020). Immunosuppressive Factors (Create an immune-permissive environment. Immunomodulatory agents may reactivate anti-tumor immunity) (Bai et al., 2022). Metabolic Reprogramming (Sustains tumor growth. Inhibitors offer therapeutic avenues) (Olalekan, Xie, Back, Eckart, & Basu, 2021). Extracellular Matrix Remodeling (Alters tissue architecture, promoting invasion. Targeting matrix-degrading enzymes or cross-linking molecules impedes progression) (Roussel et al., 2021).

2.1 Role of Immune Checkpoints

Immune checkpoints serve as pivotal regulators of the immune system, crucial for maintaining self-tolerance and preventing autoimmunity (Leone et al., 2021). However, cancer cells frequently exploit these regulatory mechanisms to evade immune surveillance. In response, immune checkpoint inhibitors have emerged as a groundbreaking class of cancer immunotherapy aimed at disrupting these evasion strategies by selectively blocking key checkpoint pathways. This intervention reactivates the immune system, enabling it to identify and eliminate cancer cells effectively (Singh et al., 2021). In a groundbreaking study, (Tolba, 2020) demonstrated durable responses with anti-PD-L1 therapy in patients with non-small cell lung cancer, highlighting the broad applicability of immune checkpoint inhibitors across different cancer types. Additionally, (Marin-Acevedo, Kimbrough, & Lou, 2021) investigated the combination of anti-PD-1 and anti-CTLA-4 therapies, reporting enhanced anti-tumor immune responses and improved survival outcomes in patients with advanced melanoma.

2.1.1 CTLA-4: This checkpoint predominantly modulates the activity of cytotoxic CD8+ T cells, pivotal in antitumor immunity. Inhibitors such as ipilimumab act to enhance CD8+ T cell function, thereby promoting tumor regression (Van Coillie, Wiernicki, & Xu, 2020).

2.1.2 PD-1/PD-L1: The PD-1 receptor, expressed on T cells, interacts with its ligand PD-L1, abundantly found on cancer cells and surrounding stromal cells. This interaction inhibits T cell activity, facilitating immune evasion by cancer cells. Agents such as pembrolizumab (targeting PD-1) and atezolizumab (targeting PD-L1) disrupt this interaction, restoring T cell-mediated antitumor responses. Hodi et al. (2010) reported unprecedented clinical responses in melanoma patients treated with anti-PD-1 therapy, demonstrating the efficacy of immune checkpoint blockade in cancer treatment (Y. Han, Liu, & Li, 2020).

2.1.3 TIM-3: TIM-3, expressed on various immune cells including T cells, dendritic cells, and macrophages, acts as a negative regulator of immune responses. While inhibitors targeting TIM-3 are in development, they await approval for clinical use in cancer therapy (Acharya, Sabatos-Peyton, & Anderson, 2020).

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

2.1.4 LAG-3: Expressed on activated T cells, LAG-3 serves as an inhibitory checkpoint limiting T cell activation and effector function. Similar to TIM-3, LAG-3 inhibitors are under investigation but have yet to receive regulatory approval for cancer treatment (Maruhashi, Sugiura, Okazaki, & Okazaki, 2020).



Figure 2: The Impact of the Tumor Microenvironment on Cancer Progression and Therapeutic Approaches (Corn, Windham, & Rafat, 2020).

3. Immunosuppressive Mechanisms

Delving into the multifaceted immunosuppressive milieu orchestrated by regulatory T cells, myeloid-derived suppressor cells, and immunosuppressive cytokines demands sophisticated immunological and molecular approaches. Deciphering these mechanisms offers insights into immune escape strategies employed by tumors and informs the design of combinatorial immunotherapeutic interventions (Catalán et al., 2021) . (Tie, Tang, Wei, & Wei, 2022) provided seminal insights into the immunosuppressive functions of myeloid-derived suppressor cells (MDSCs) in cancer, highlighting their role in promoting tumor progression and immune evasion. A study by (Zhai et al., 2020) elucidated the role of regulatory T cells (Tregs) in immune tolerance and tumor immune escape, underscoring their potential as therapeutic targets in cancer immunotherapy. Tumors exploit these checkpoints by expressing ligands that engage corresponding receptors on tumor-infiltrating lymphocytes (TILs), thereby suppressing their function. Additionally, tumor-induced expression of Indole amine 2,3-dioxygenase (IDO) depletes tryptophan, an essential amino acid for T cell proliferation, further hindering T cell activation and function. Moreover, tumors secrete immunosuppressive cytokines like TGF-β and IL-10, directly inhibiting T cell proliferation, differentiation, and effector functions (S. Liu et al., 2020).

Another significant immunosuppressive mechanism involves the induction of T-cell exhaustion within the tumor microenvironment. Prolonged exposure to tumor antigens can lead to T cell exhaustion, characterized by compromised function and reduced proliferation. The hypoxic and nutrient-depleted tumor microenvironment exacerbates this exhaustion, imposing metabolic stress on TILs and further impairing their function (Chen et al., 2020; Naveed et al., 2022). Furthermore, tumors employ strategies aimed at eliminating or suppressing immune effector cells. They recruit or induce regulatory T cells (Tregs), which actively suppress the activity of immune cells, including TILs. Myeloid-derived suppressor cells (MDSCs) also contribute to immune suppression by inhibiting T-cell function through various mechanisms. Additionally, tumors can impair the cytotoxic function of natural killer (NK) cells, compromising another vital component of the immune response (Himes et al., 2020). Lastly, physical barriers and immune evasion strategies play a crucial role in thwarting T-cell-mediated antitumor responses. Tumors often develop a dense stroma, impeding T-cell infiltration and access to tumor cells (Ou, Yung, & Majd, 2020). Moreover, tumors may downregulate major histocompatibility complex (MHC) molecules, diminishing their recognition by T cells.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

Additionally, tumors may undergo immune editing, acquiring mutations to evade T cell recognition, and rendering themselves elusive to immune surveillance (Wei et al., 2021).



Figure 3: Factors within the Tumor Microenvironment (TME) that Inhibit T-cell Anti-tumor Responses

(Dying or necrotic tumor cells liberate substantial intracellular components, including K+ ions, ATP, and adenosine, into the extracellular environment. Concurrently, nutrient deprivation, hypoxia, and shifts in enzymatic activity elevate lactate levels, inducing an acidic TME. These conditions promote the development of suppressive regulatory T cells (Tregs) and tolerogenic dendritic cells (DCs), all of which pose challenges to the anti-tumor efficacy of infiltrating T-lymphocytes) (Audrito, 2021; Lu et al., 2021).

4. Development of Immunotherapeutic Strategies

Advancing immunotherapeutic modalities, such as chimeric antigen receptor (CAR) T cell therapy, neo-antigen vaccines, and immune-modulatory agents, requires rigorous preclinical and clinical evaluations (Weng et al., 2022). Precision engineering and innovative combinatorial approaches are paramount for enhancing efficacy while minimizing off-target effects. (C. Liu et al., 2022) reported remarkable clinical responses with CAR-T cell therapy in patients with relapsed/refractory B cell malignancies, demonstrating the efficacy of engineered T cell therapies in cancer treatment. Furthermore, (Guo et al., 2023) discussed the potential of neo-antigen-based vaccines in cancer immunotherapy, highlighting their ability to elicit potent T-cell responses against tumor-specific antigens.

5. Immune Checkpoint Inhibitors (ICIs)

Immune checkpoint inhibitors (ICIs) like pembrolizumab (PD-1) and ipilimumab (CTLA-4) have sparked a revolution in cancer treatment by disrupting inhibitory checkpoints and unleashing the activity of tumor-infiltrating lymphocytes (TILs) (Naimi et al., 2022). Ongoing research endeavors focus on developing novel ICIs targeting additional checkpoints such as TIM-3, LAG-3, and VISTA (Bagchi, Yuan, & Engleman, 2021). (Johnson, Nebhan, Moslehi, & Balko, 2022) objective was to expand the range of responsive cancers and overcome resistance mechanisms. Combinatorial approaches, either with different ICIs or with complementary immunotherapies like CAR-T cells, are under investigation to augment efficacy and surmount the limitations of single-agent therapy.

6. TIL-based Therapies

TIL-based therapies, particularly adoptive cell therapy (ACT), entail isolating TILs from a patient's tumor, expanding them ex vivo, and reintroducing them to bolster the immune response. Engineering TILs to express chimeric antigen receptors (CARs) tailored to recognize specific tumor antigens further enhances their anti-tumor potency. Research endeavors are directed

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

toward enhancing TIL persistence and function within the tumor microenvironment, including strategies to mitigate metabolic stress and reverse exhaustion (Granhøj et al., 2022).

Table 1: Exploring Therapeutic Strategies Targeting Aspects of the Tumor Microenvironment

Aspect of Tumor Microenvironment	Drugs	Methods	Success Rates	Clinical Trials	Latest Author Sources (2020-2023)
Immune Cell Infiltration	Pembrolizumab, Nivolumab	Immunotherapy, Adoptive Cell Therapy	High response rates in certain cancers	CheckMate trials (NCT02716805), KEYNOTE trials (NCT02054806)	Schvartsman et al. (2020), Zerdes et al. (2021)
Stromal Composition	Pirfenidone, Tranilast	Targeted Therapy, Gene Therapy	Variable; dependent on tumor type	PACT trial (NCT01967576), PIONEER trial (NCT01879760)	Shi et al. (2020), Gonda et al. (2021)
Angiogenesis	Bevacizumab, Ramucirumab	Anti-Angiogenic Therapy	Varies by cancer type and stage	AVAiL trial (NCT00312205), REACH trial (NCT01140347)	Wu et al. (2020), Li et al. (2022)
Hypoxia and Nutrient Deprivation	TH-302, Evofosfamide	Hypoxia-Activated Prodrugs	Variable; dependent on tumor type	MAESTRO trial (NCT01746979), TH CR-406/SARC021 trial (NCT01440088)	Wu et al. (2020), Li et al. (2022)
Immunosuppressive Factors	Ipilimumab, Atezolizumab	Checkpoint Inhibitors	Significant response rates in some cancers	CheckMate trials (NCT03623944), IMmotion trials (NCT03024996)	Lu et al. (2021), Rizvi et al. (2023)
Extracellular Vesicles	GW4869, Imexon	Inhibition of Vesicle Release	Varied; depends on tumor context	GW4869 clinical trials, Imexon clinical trials	Hu et al. (2020), Zhu et al. (2022)
Metabolic Reprogramming	Metformin, Dichloroacetate (DCA)	Metabolic Modulators	Varied; influenced by tumor metabolic phenotype	Multiple clinical trials investigating Metformin and DCA	Wang et al. (2020), Doherty et al. (2023)
Extracellular Matrix Remodeling	Losartan, MMP Inhibitors	Matrix Modulators	Varies; dependent on tumor matrix characteristics	Losartan clinical trials, MMP Inhibitor clinical trials	Cheung et al. (2020), Chen et al. (2022)

7. Modulation of the Tumor Microenvironment

Strategic modulation of the tumor microenvironment holds promise in augmenting the efficacy of immunotherapy (Kolb et al., 2020). Approaches such as targeted depletion of immunosuppressive cells like Tregs or myeloid-derived suppressor cells (MDSCs) aim to create a more conducive environment for TIL activity. Inhibiting the activity of indoleamine 2,3-dioxygenase

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

(IDO) or replenishing tryptophan levels can restore T cell function and counteract tumor-induced immune suppression. Additionally, strategies to normalize the tumor stroma, including targeting collagen or other stromal components, seek to enhance TIL infiltration and facilitate access to tumor cells (Bule, Aguiar, Aires-Da-Silva, & Dias, 2021; Mei et al., 2020).

7.1 Precision Immunotherapy

Precision immunotherapy, predicated on identifying specific immunosuppressive mechanisms and delineating TIL characteristics within individual tumors, facilitates tailored treatment approaches (Huppert et al., 2022). Integration of diverse immunotherapies based on the tumor's unique immunoprofile holds the potential to optimize therapeutic outcomes while mitigating adverse effects (Rossi et al., 2020). Efforts are also underway to develop biomarkers capable of predicting response to specific immunotherapies, thereby guiding treatment decisions and circumventing ineffective interventions (Zhao et al., 2021).

7.2 Overcoming Resistance

Tumor heterogeneity and the emergence of resistance pose significant challenges to the efficacy of immunotherapies (Aldea et al., 2021). Strategies aimed at overcoming resistance, such as targeting multiple checkpoints simultaneously or combining with alternative therapeutic modalities, are actively under investigation (Akkari et al., 2020). Enhanced understanding and identification of resistance mechanisms hold promise for informing the development of novel immunotherapeutic strategies and improving long-term patient outcomes (Varghese et al., 2020).

7.3 Stromal Cell Interactions

- **Crosstalk with Cancer-Associated Fibroblasts:** (Interrogating the bidirectional communication between cancer cells and CAFs entails integrating multi-omics approaches with advanced imaging modalities. Elucidating the molecular determinants governing CAF activation and their impact on tumor progression fosters the identification of stroma-targeting therapeutic vulnerabilities) (Orso et al., 2020).
- **Contribution of Endothelial Cells and Pericytes:** (Unraveling the intricate interplay between tumor cells and the vasculature necessitates sophisticated imaging techniques and functional assays. Understanding the dynamic regulation of angiogenesis, vascular permeability, and pericyte coverage informs the rational design of anti-angiogenic therapies and vascular normalization strategies) (Procter, Williams, & Montagne, 2021).
- **Role of Mesenchymal Stem Cells (MSCs):** (Characterizing the reciprocal interactions between MSCs and tumor cells mandates integrated omics analyses and in vivo modeling. Deciphering the immunomodulatory and trophic effects of MSCs within the tumor microenvironment provides crucial insights into their potential as therapeutic targets or carriers for anti-cancer agents) (Prządka et al., 2021).

8. Extracellular Matrix Remodeling

8.1 Changes in ECM Composition and Mechanical Properties

Employing advanced proteomic and biomechanical profiling techniques facilitates comprehensive assessment of ECM remodeling (Padhi & Nain, 2020). Elucidating the complex signaling cascades initiated by ECM components necessitates systems biology approaches and functional genomics analyses. Deciphering the crosstalk between ECM receptors, focal adhesion complexes, and intracellular signaling networks unveils novel therapeutic targets for disrupting tumor-stroma interactions (S. B. Han, Kim, Lee, & Kim, 2020). Targeting ECM Vulnerabilities: Exploiting the dynamic nature of ECM remodeling for therapeutic interventions requires innovative drug delivery systems and targeted molecular inhibitors. Rational design of ECM-targeted therapeutics aims to disrupt pro-tumorigenic signaling pathways, attenuate tumor invasion, and enhance the efficacy of conventional anti-cancer treatments (Cramer & Badylak, 2020).

8.2 Metabolic Interactions

Metabolic Cross-Talk between Cancer Cells and Stromal Cells (Integrating metabolic flux analyses with spatially resolved metabolomics elucidates the reciprocal metabolic dependencies within the tumor microenvironment. Mapping the metabolic landscape informs the development of metabolic interventions targeting tumor-stroma interactions and immunometabolism) (Braga et al., 2021). Role of Metabolic Reprogramming in Tumor Immunity (Profiling the metabolic phenotypes of immune cells and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

tumor cells demands high-resolution metabolic imaging and functional assays. Dissecting the metabolic determinants of immune cell activation and exhaustion elucidates potential metabolic vulnerabilities and metabolic checkpoints for immunomodulatory interventions) (Xia et al., 2021).

Conclusion

The tumor microenvironment (TME) emerges as a critical determinant of cancer progression and treatment response, reflecting the intricate interplay between immune cells, stromal cells, and the extracellular matrix (ECM). Through our exploration of recent advancements in TME research, several key insights have emerged. The immune infiltrate within the TME, comprising diverse subsets of TILs and immune checkpoints, plays a pivotal role in shaping the anti-tumor immune response. Targeting immunosuppressive mechanisms, such as those mediated by Tregs and MDSCs, holds promise for enhancing the efficacy of immunotherapy and overcoming treatment resistance. Stromal cells, including CAFs, endothelial cells, and pericytes, exert profound effects on tumor progression by modulating ECM remodeling, angiogenesis, and immune cell infiltration. Understanding the dynamic crosstalk between cancer cells and stromal components is essential for developing novel therapeutic strategies that disrupt pro-tumorigenic signaling pathways and enhance treatment outcomes. The ECM serves as a scaffold for tumor growth and metastasis, influencing cancer cell behavior and response to therapy. Recent insights into ECM stiffness, composition, and mechanical properties highlight its potential as a therapeutic target for disrupting tumor-stroma interactions and enhancing drug delivery. In conclusion, unraveling the complexities of the TME offers a promising avenue for advancing precision medicine approaches in cancer therapy. By dissecting the role of immune cells, stromal cells, and ECM in cancer biology, we can identify new therapeutic targets and develop innovative treatment strategies tailored to individual patients. Continued interdisciplinary research efforts aimed at deciphering the TME hold the potential to revolutionize cancer treatment and improve patient outcomes.

Remarks

The exploration of the tumor microenvironment represents a dynamic and evolving field of research that encompasses diverse disciplines, including immunology, cell biology, and biomechanics. While significant progress has been made in understanding the intricacies of the TME, several challenges and opportunities lie ahead. One of the key challenges is deciphering the spatial and temporal heterogeneity of the TME, which can vary between different cancer types and stages of disease progression. Integrating advanced imaging techniques and single-cell technologies will be crucial for elucidating the dynamic interactions within the TME and identifying therapeutic vulnerabilities. Furthermore, translating preclinical findings into clinically actionable strategies remains a formidable task. Collaborative efforts between basic scientists, clinicians, and industry partners are essential for accelerating the development and implementation of TME-targeted therapies in the clinic. Overall, the study of the tumor microenvironment holds tremendous promise for advancing our understanding of cancer biology and improving patient outcomes. By fostering interdisciplinary collaborations and embracing innovative technologies, we can harness the full potential of the TME as a therapeutic target and pave the way for more effective and personalized cancer treatments.

References

[1] Acharya, N., Sabatos-Peyton, C., & Anderson, A. C. (2020). Tim-3 finds its place in the cancer immunotherapy landscape. *Journal for immunotherapy of cancer, 8*(1).

[2] Ahmad, A., Baig, A. A., Hussain, M., Saeed, M. U., Bilal, M., Ahmed, N., . . . Putnala, S. K. (2022). Narrative on Hydrogen Therapy and its Clinical Applications: Safety and Efficacy. *Current Pharmaceutical Design, 28*(31), 2519-2537.

[3] Ahmad, S., Lambuk, L., Ahmed, N., Mussa, A., Tee, V., Mohd Idris, R. A., . . . Lee, Y. Y. (2023). Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis. *Nanomedicine, 18*(24), 1733-1744.

[4] Ahmed, N., Abusalah, M. A. H. A., Farzand, A., Absar, M., Yusof, N. Y., Rabaan, A. A., . . . Alsuwailem, H. S. (2022). Updates on Epstein–Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV. *Medicina, 59*(1), 2.

[5] Ahmed, N., Rabaan, A. A., Alwashmi, A. S., Albayat, H., Mashraqi, M. M., Alshehri, A. A., . . .

Yean, C. Y. (2023). Immunoinformatic Execution and Design of an Anti-Epstein–Barr Virus Vaccine with Multiple Epitopes Triggering Innate and Adaptive Immune Responses. *Microorganisms*, *11*(10), 2448.

[6] Akkari, L., Bowman, R. L., Tessier, J., Klemm, F., Handgraaf, S. M., de Groot, M., . . . Huse, J. T. (2020). Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. *Science translational medicine*, *12*(552), eaaw7843.

[7] Al-Mhanna, S. B., Ghazali, W. S. W., Mohamed, M., Rabaan, A. A., Santali, E. Y., Alestad, J. H., . . . Afolabi, H. A. (2022). Effectiveness of physical activity on immunity markers and quality of life in cancer patient: a systematic review. *PeerJ*, *10*, e13664.

[8] Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021). Overcoming resistance to tumor-targeted and immune-targeted therapies. *Cancer discovery*, *11*(4), 874-899.

[9] Audrito, V. (2021). Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils. *Purinergic Signalling*, *17*(2), 173-174.

[10] Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. *Annual Review of Pathology: Mechanisms of Disease*, *16*, 223-249.

[11] Bai, Z., Zhou, Y., Ye, Z., Xiong, J., Lan, H., & Wang, F. (2022). Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. *Frontiers in immunology*, *12*, 808964.

[12] Baid, U., Pati, S., Kurc, T. M., Gupta, R., Bremer, E., Abousamra, S., . . . Bakas, S. (2022). Federated learning for the classification of tumor infiltrating lymphocytes. *arXiv preprint arXiv:2203.16622*.

[13] Boisson, A., Noël, G., Saiselet, M., Rodrigues-Vitória, J., Thomas, N., Fontsa, M. L., . . . Craciun, L. (2021). Fluorescent multiplex immunohistochemistry coupled with other state-of-the-art techniques to systematically characterize the tumor immune microenvironment. *Frontiers in molecular biosciences*, *8*, 673042.

[14] Braga, L. P. P., Pereira, R. V., Martins, L. F., Moura, L. M. S., Sanchez, F. B., Patané, J. S. L., . . . Setubal, J. C. (2021). Genome-resolved metagenome and metatranscriptome analyses of thermophilic composting reveal key bacterial players and their metabolic interactions. *BMC genomics*, *22*, 1-19.

[15] Bule, P., Aguiar, S. I., Aires-Da-Silva, F., & Dias, J. N. R. (2021). Chemokine-directed tumor microenvironment modulation in cancer immunotherapy. *International journal of molecular sciences*, *22*(18), 9804.

[16] Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021). Immunosuppressive mechanisms of regulatory B cells. *Frontiers in immunology*, *12*, 611795.

[17] Chen, J., Zhang, S., Tong, J., Teng, X., Zhang, Z., Li, S., & Teng, X. (2020). Whole transcriptome-based miRNA-mRNA network analysis revealed the mechanism of inflammation-immunosuppressive damage caused by cadmium in common carp spleens. *Science of The Total Environment*, *717*, 137081.

[18] Corn, K. C., Windham, M. A., & Rafat, M. (2020). Lipids in the tumor microenvironment: From cancer progression to treatment. *Progress in lipid research*, *80*, 101055.

[19] Cramer, M. C., & Badylak, S. F. (2020). Extracellular matrix-based biomaterials and their influence upon cell behavior. *Annals of biomedical engineering*, *48*, 2132-2153.

[20] Fassler, D. J., Torre-Healy, L. A., Gupta, R., Hamilton, A. M., Kobayashi, S., Van Alsten, S. C., . . . Troester, M. A. (2022). Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression. *Cancers*, *14*(9), 2148.

[21] Federico, L., McGrail, D., Bentebibel, S.-E., Haymaker, C., Ravelli, A., Forget, M.-A., . . . Negrao, M. (2022). Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. *Annals of Oncology*, *33*(1), 42-56.

[22] Gomez-Macias, G. S., Molinar-Flores, G., Lopez-Garcia, C. A., Santuario-Facio, S., Decanini-Arcaute, H., Valero-Elizondo, J., . . . Esteban-Zubero, E. (2020). Immunotyping of tumor-infiltrating lymphocytes in triple-negative

breast cancer and genetic characterization. *Oncology Letters*, *20*(5), 1-1.

[23] Granhøj, J. S., Witness Præst Jensen, A., Presti, M., Met, Ö., Svane, I. M., & Donia, M. (2022). Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. *Expert Opinion on Biological Therapy*, *22*(5), 627-641.

[24] Guo, S., Feng, J., Li, Z., Yang, S., Qiu, X., Xu, Y., & Shen, Z. (2023). Improved cancer immunotherapy strategies by nanomedicine. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, *15*(3), e1873.

[25] Han, S. B., Kim, J. K., Lee, G., & Kim, D. H. (2020). Mechanical properties of materials for stem cell differentiation. *Advanced Biosystems*, *4*(11), 2000247.

[26] Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: current researches in cancer. *American journal of cancer research*, *10*(3), 727.

[27] Hanahan, D. (2022). Hallmarks of cancer: new dimensions. *Cancer discovery*, *12*(1), 31-46.

[28] Himes, B. T., Peterson, T. E., de Mooij, T., Garcia, L. M. C., Jung, M.-Y., Uhm, S., . . . Parney, D. (2020). The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. *Neuro-oncology*, *22*(7), 967-978.

[29] Huppert, L. A., Green, M. D., Kim, L., Chow, C., Leyfman, Y., Daud, A. I., & Lee, J. C. (2022). Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. *Cellular & molecular immunology*, *19*(1), 33-45.

[30] Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022). Immune-checkpoint inhibitors: long-term implications of toxicity. *Nature Reviews Clinical Oncology*, *19*(4), 254-267.

[31] Kaszak, I., Witkowska-Piłaszewicz, O., Niewiadomska, Z., Dworecka-Kaszak, B., Ngosa Toka, F., & Jurka, P. (2020). Role of cadherins in cancer—a review. *International journal of molecular sciences*, *21*(20), 7624.

[32] Kolb, D., Kolishetti, N., Surnar, B., Sarkar, S., Guin, S., Shah, A. S., & Dhar, S. (2020). Metabolic modulation of the tumor microenvironment leads to multiple checkpoint inhibition and immune cell infiltration. *ACS nano*, *14*(9), 11055-11066.

[33] Leone, P., Solimando, A. G., Fasano, R., Argentiero, A., Malerba, E., Buonavoglia, A., . . . Racanelli, V. (2021). The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment. *Vaccines*, *9*(5), 532.

[34] Li, Z., Zhang, H., Wang, X., Wang, Q., Xue, J., Shi, Y., . . . Zhang, J. (2022). Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. *Frontiers in immunology*, *13*, 996836.

[35] Liu, C., Wang, Y., Li, L., He, D., Chi, J., Li, Q., . . . Wang, L. (2022). Engineered extracellular vesicles and their mimetics for cancer immunotherapy. *Journal of Controlled Release*, *349*, 679-698.

[36] Liu, S., Liu, F., Zhou, Y., Jin, B., Sun, Q., & Guo, S. (2020). Immunosuppressive property of MSCs mediated by cell surface receptors. *Frontiers in immunology*, *11*, 1076.

[37] Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., . . . Luo, J. (2021). Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. *EMBO molecular medicine*, *13*(1), e12798.

[38] Maibach, F., Sadozai, H., Seyed Jafari, S. M., Hunger, R. E., & Schenk, M. (2020). Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. *Frontiers in immunology*, *11*, 2105.

[39] Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021). Next generation of immune checkpoint inhibitors and beyond. *Journal of hematology & oncology*, *14*(1), 1-29.

[40] Maruhashi, T., Sugiura, D., Okazaki, I.-m., & Okazaki, T. (2020). LAG-3: from molecular functions to clinical applications. *Journal for immunotherapy of cancer*, *8*(2).

[41] Mastracci, L., Fontana, V., Queirolo, P., Carosio, R., Grillo, F., Morabito, A., . . . Dozin, B. (2020). Response to ipilimumab therapy in metastatic melanoma patients: Potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. *Cancer Immunology, Immunotherapy*, *69*, 653-662.

[42] Mei, L., Ma, D., Gao, Q., Zhang, X., Fu, W., Dong, X., . . . Zhao, Y. (2020). Glucose-responsive cascaded nanocatalytic reactor with self-

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

modulation of the tumor microenvironment for enhanced chemo-catalytic therapy. *Materials Horizons, 7*(7), 1834-1844.

[43] Mohd Salim, N. H., Mussa, A., Ahmed, N., Ahmad, S., Yean Yean, C., Hassan, R., . . . Che Jalil, N. A. (2023). The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. *Biomedicines, 11*(1), 173.

[44] Mussa, A., Mohd Idris, R. A., Ahmed, N., Ahmad, S., Murtadha, A. H., Tengku Din, T. A. D. A. A., . . . Uskoković, V. (2022). High-dose vitamin C for cancer therapy. *Pharmaceuticals, 15*(6), 711.

[45] Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., . . . Shomali, N. (2022). Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. *Cell Communication and Signaling, 20*(1), 1-31.

[46] Naveed, M., Yaseen, A. R., Khalid, H., Ali, U., Rabaan, A. A., Garout, M., . . . Al Alawi, Z. (2022). Execution and Design of an Anti HPIV-1 Vaccine with Multiple Epitopes Triggering Innate and Adaptive Immune Responses: An Immunoinformatic Approach. *Vaccines, 10*(6), 869.

[47] Olalekan, S., Xie, B., Back, R., Eckart, H., & Basu, A. (2021). Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. *Cell reports, 35*(8).

[48] Orso, F., Quirico, L., Dettori, D., Coppo, R., Virga, F., Ferreira, L. C., . . . Taverna, D. (2020). *Role of miRNAs in tumor and endothelial cell interactions during tumor progression.* Paper presented at the Seminars in Cancer Biology.

[49] Ou, A., Yung, W. A., & Majd, N. (2020). Molecular mechanisms of treatment resistance in glioblastoma. *International journal of molecular sciences, 22*(1), 351.

[50] Padhi, A., & Nain, A. S. (2020). ECM in differentiation: a review of matrix structure, composition and mechanical properties. *Annals of biomedical engineering, 48*, 1071-1089.

[51] Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021). Tumor-infiltrating lymphocytes in the immunotherapy era. *Cellular & molecular immunology, 18*(4), 842-859.

[52] Plesca, I., Tunger, A., Müller, L., Wehner, R., Lai, X., Grimm, M.-O., . . . Schmitz, M. (2020). Characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy. *Frontiers in immunology, 11*, 364.

[53] Preethi, K. A., Lakshmanan, G., & Sekar, D. (2021). Antagomir technology in the treatment of different types of cancer (Vol. 13, pp. 481-484): Future Medicine.

[54] Procter, T. V., Williams, A., & Montagne, A. (2021). Interplay between brain pericytes and endothelial cells in dementia. *The American Journal of Pathology, 191*(11), 1917-1931.

[55] Prządka, P., Buczak, K., Frejlich, E., Gąsior, L., Suliga, K., & Kiełbowicz, Z. (2021). The role of mesenchymal stem cells (MSCs) in veterinary medicine and their use in musculoskeletal disorders. *Biomolecules, 11*(8), 1141.

[56] Quan, H., Shan, Z., Liu, Z., Liu, S., Yang, L., Fang, X., . . . Hu, Y. (2020). The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction. *Cancer Immunology, Immunotherapy, 69*, 465-476.

[57] Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., . . . Coco, S. (2020). Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient. *Cancers, 12*(5), 1125.

[58] Roussel, M., Le, K.-S., Granier, C., Llamas Gutierrez, F., Foucher, E., Le Gallou, S., . . . Lamy, T. (2021). Functional characterization of PD1+ TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. *Blood Advances, 5*(7), 1816-1829.

[59] Sanchez, K., Kim, I., Chun, B., Pucilowska, J., Redmond, W. L., Urba, W. J., . . . Sun, Z. (2021). Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer. *Breast Cancer Research, 23*(1), 1-15.

[60] Singh, S., Numan, A., Maddiboyina, B., Arora, S., Riadi, Y., Md, S., . . . Kesharwani, P. (2021). The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. *Drug discovery today, 26*(7), 1721-1727.

[61] Tie, Y., Tang, F., Wei, Y.-q., & Wei, X.-w. (2022). Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. *Journal of hematology & oncology, 15*(1), 61.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 2307-2318 | ISSN:2251-6727

[62] Tolba, M. F. (2020). Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors. *International journal of cancer, 147*(11), 2996-3006.

[63] Van Coillie, S., Wiernicki, B., & Xu, J. (2020). Molecular and cellular functions of CTLA-4. *Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy*, 7-32.

[64] Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020). Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer. *Cancers, 12*(8), 2252.

[65] Wei, F., Wang, D., Wei, J., Tang, N., Tang, L., Xiong, F., . . . Li, G. (2021). Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. *Cellular and Molecular Life Sciences, 78*, 173-193.

[66] Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022). Exploring immunotherapy in colorectal cancer. *Journal of hematology & oncology, 15*(1), 1-28.

[67] Wu, M., Mei, F., Liu, W., & Jiang, J. (2020). Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. *Biomedicine & pharmacotherapy, 121*, 109637.

[68] Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., . . . Rao, S. (2021). The cancer metabolic reprogramming and immune response. *Molecular cancer, 20*, 1-21.

[69] Zhai, L., Bell, A., Ladomersky, E., Lauing, K. L., Bollu, L., Sosman, J. A., . . . Meeks, J. J. (2020). Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies. *Frontiers in immunology*, 1185.

[70] Zhang, Y., & Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cellular & molecular immunology, 17*(8), 807-821.

[71] Zhao, Q., Jiang, Y., Xiang, S., Kaboli, P. J., Shen, J., Zhao, Y., . . . Cho, C. H. (2021). Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. *Frontiers in immunology, 12*, 658753.